When was 1910 Genetics founded?

1910 Genetics was founded in 2018.

Where is 1910 Genetics located?

1910 Genetics is headquartered in Cambridge, United States.

Who is the current CEO of 1910 Genetics?

Jen Nwankwo of 1910 Genetics. They have also founded 1 company.

How many employees does 1910 Genetics have?

As of Mar 31, 2026, the latest employee count at 1910 Genetics is 47.

Is 1910 Genetics a funded company?

1910 Genetics is a funded company, having raised a total of $29.8M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of 1910 Genetics?

1910 Genetics' latest funding was a $***** Series A round on Oct 31, 2024, with participation from 1 investor.

Where does 1910 Genetics rank among its competitors?

1910 Genetics ranks 45th amongst 150 active competitors, of which 64 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was XtalPi, which secured $268M in Sep, 2025.

Who are the top competitors of 1910 Genetics?

1910 Genetics' top competitors include Recursion Pharmaceuticals, Healx and XtalPi. Among them, XtalPi secured the most recent funding round in September, 2025.

1910 Genetics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small molecule therapeutics to treat pain and aging-related diseases. It is a biotechnology company that integrates AI, computation, and biological automation to accelerate the design of small molecule and protein therapeutics. The company have developed two discovery engines ELVIS and ROSALYND that enable to design drug candidates.

Website: www.1910genetics.com
Email ID: *****@1910genetics.com

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Series A

Total Funding

$29.8M in 5 rounds

Latest Funding Round

Series A, Oct 31, 2024, $*****

Investors

Y Combinator & 12 more

Ranked

45^th among 150 active competitors

Employee Count

47 as on Mar 31, 2026

Similar Companies

Innovaccer & 2449 more

View 1910 Genetics' full profile

1910 Genetics has raised a total funding of $29.8M over 5 rounds. Its latest funding round was a Series A round on Oct 31, 2024 for $*****. 1 investor participated in its latest round. 1910 Genetics has 11 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of 1910 Genetics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 31, 2024	1235153	Series A	8116482	4640828	6079536	9236564
Sep 30, 2021	7015320	Grant (prize money)	2254984	7405021	6921469	NIH
Jul 01, 2021	8876828	Grant (prize money)	2583606	5551179	9132181	HHS

Access funding benchmarks and valuations. Sign up today!

View details of 1910 Genetics's funding rounds and investors

The founders of 1910 Genetics is Jen Nwankwo. Jen Nwankwo is the CEO of 1910 Genetics.

Here are the details of 1910 Genetics' key team members:

Jen Nwankwo: Founder & CEO of 1910 Genetics.
Contact Info: 1 email address

View details of 1910 Genetics's Founder profiles and Board Members

1910 Genetics' employee count trend

1910 Genetics has 47 employees as of Mar 26. Here is 1910 Genetics's employee count trend over the years:

Uncover 1910 Genetics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 1910 Genetics include Recursion Pharmaceuticals, Healx and XtalPi. Here is the list of Top 10 competitors of 1910 Genetics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 46 others	72/100
2nd	Healx 2014, Cambridge (United Kingdom), Series C	AI-powered drug discovery platform to treat rare diseases	$115M	Atomico, Balderton Capital & 18 others	69/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Tencent, SoftBank Vision Fund & 25 others	67/100
4th	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates Foundation, WuXi AppTec & 16 others	66/100
5th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
6th	METiS Therapeutics 2017, Cambridge (United States), Series B	Provider of an AI-assisted platform for drug discovery and development	$252M	Sequoia Capital China, Luminous Ventures ... & 13 others	63/100
7th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	62/100
8th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Warburg Pincus & 36 others	62/100
9th	Gero 2015, Singapore (Singapore), Series A	Developer of reverse engineering technology for controlling aging	$13.5M	Bulba Ventures, Melnichek Investments & 13 others	62/100
10th	Isomorphic Labs 2021, London (United Kingdom), Series D	AI-driven platform to accelerate drug discovery process	$600M	Thrive Capital, Alphabet & 1 others	62/100
45th	1910 Genetics 2018, Cambridge (United States), Series A	Developer of small molecule therapeutics to treat pain and aging-related diseases	$29.8M	New Ventures Funds, Point Reyes Management ... & 11 others	44/100